Lynch Michael C, Straub Renee, Adams David R
Pennsylvania State University College of Medicine, Hershey, PA, USA.
J Drugs Dermatol. 2011 Mar;10(3):308-10.
Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors. Commonly administered for the treatment of metastatic or unresectable hepatocellular carcinoma and advanced renal cell carcinoma, sorafenib has demonstrated remarkable survival benefits for those where curative surgery is not an option. Although generally having a mild side effect profile, sorafenib has been linked to a variety of dermatologic disorders, including most commonly acneiform rash, hand-foot-skin reactions, facial erythema, splinter subungual hemorrhages, alopecia or pruritus. The authors describe a case of sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient with hepatocellular carcinoma. This case adds to the growing literature suggesting a strong correlation between sorafenib and non-melanoma skin cancers including keratoacanthoma and squamous cell carcinoma. Routine dermatologic monitoring of these patients to ensure early detection is highly recommended. J Drugs Dermatol. 2011;10(3):308-310.
索拉非尼是一种多激酶抑制剂，在实体瘤治疗中具有抗增殖和抗血管生成特性。索拉非尼常用于治疗转移性或不可切除的肝细胞癌以及晚期肾细胞癌，对于那些无法进行根治性手术的患者，它已显示出显著的生存益处。尽管索拉非尼的副作用通常较轻，但它与多种皮肤病有关，最常见的包括痤疮样皮疹、手足皮肤反应、面部红斑、甲下裂片样出血、脱发或瘙痒。作者描述了一例肝细胞癌患者出现具有角化棘皮瘤样特征的索拉非尼诱导的爆发性鳞状细胞癌病例。该病例增加了越来越多的文献报道，表明索拉非尼与包括角化棘皮瘤和鳞状细胞癌在内的非黑色素瘤皮肤癌之间存在密切关联。强烈建议对这些患者进行常规皮肤科监测以确保早期发现。《药物皮肤病学杂志》。2011年；10(3):308 - 310。
